Abstract:Background: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based approach in predicting different cardiovascular outcomes. Methods: Among 51 859 UK Biobank participants (mean age, 56.7 years; 45.5% male) without cardiovascular disease and with proteomics measurements, we examined the primary composite outcome of fatal and nonfatal coronary heart disease, stroke, or heart failure (major adverse cardiovascular events), as well as additional secondary cardiovascular outcomes. An exposome-wide association study was conducted using relative protein concentrations, adjusted for a range of classic, demographic, and lifestyle risk factors. A prediction model using only age, sex, and protein markers (protein model) was developed using a least absolute shrinkage and selection operator-regularized approach (derivation: 80% of cohort) and validated using split-sample testing (20% of cohort). Their performance was assessed by comparing calibration, net reclassification index, and c statistic with the PREVENT (Predicting Risk of CVD Events) risk score. Results: Over a median 13.6 years of follow-up, 4857 participants experienced first major adverse cardiovascular events. After adjustment, the proteins most strongly associated with major adverse cardiovascular events included NT-proBNP (N-terminal pro B-type natriuretic peptide; hazard ratio [HR], 1.68 per SD increase), proADM (pro-adrenomedullin; HR, 1.60), GDF-15 (growth differentiation factor-15; HR, 1.47), WFDC2 (WAP four-disulfide core domain protein 2; HR, 1.46), and IGFBP4 (insulin-like growth factor-binding protein 4; HR, 1.41). In total, 222 separate proteins were predictors of all outcomes of interest in the protein model, and 86 were selected for the primary outcome specifically. In the validation cohort, compared with the PREVENT risk factor model, the protein model improved calibration, net reclassification (net reclassification index +0.09), and c statistic for major adverse cardiovascular events (+0.051). The protein model also improved the prediction of other outcomes, including ASCVD (c statistic +0.035), myocardial infarction (+0.023), stroke (+0.024), aortic stenosis (+0.015), heart failure (+0.060), abdominal aortic aneurysm (+0.024), and dementia (+0.068). Conclusions: Measurement of targeted protein biomarkers produced superior prediction of aggregated and disaggregated cardiovascular events. This study represents an important proof of concept for the application of targeted proteomics in predicting a range of cardiovascular outcomes.

Plasma proteomic biomarkers and the association between poor cardiovascular health and incident dementia: The UK Biobank study

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Mediating and moderating effects of plasma proteomic biomarkers on the association between poor oral health problems and incident dementia: The UK Biobank study

Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank

Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults

Plasma Proteomic Profiles Predict Future Dementia in Healthy Adults

Hospital-treated prevalent infections, the plasma proteome and incident dementia among UK older adults

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

Plasma metabolic profiles predict future dementia and dementia subtypes: a prospective analysis of 274,160 participants

Cardiovascular Risk Burden in Relation to Dementia and Brain Structural and Metabolic Imaging Markers

Healthy lifestyles, plasma proteomic profile and long-term risk of dementia

Abstract 13280: Proteomic Indicators of Cardiovascular Health Relate to Brain Volume and Dementia Risk

Unraveling the role of plasma proteins in dementia: insights from two cohort studies in the UK, with causal evidence from Mendelian randomization

Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study

Abstract 13245: Cardiovascular Risk Burden in Relation to Dementia and Brain Structural Imaging Markers: A Study from UK Biobank

Mediating and moderating effects of plasma proteomic biomarkers on the association between poor oral health problems and brain white matter microstructural integrity: the UK Biobank study

Plasma metabolomic signature of healthy lifestyle, structural brain reserve and risk of dementia

Plasma Biomarkers as Predictors of Progression to Dementia in Individuals with Mild Cognitive Impairment

Proteomic Analyses Reveal Plasma EFEMP1 and CXCL12 As Biomarkers and Determinants of Neurodegeneration.

Serum clinical laboratory tests and risk of incident dementia: a prospective cohort study of 407,190 individuals